Dynamics of ligand binding to GPCR: Residence time of melanocortins and its modulation

Pharmacological Research

Volumn 113, Issue , 2016, Pages 747-753

  Rinken, Ago ^a   Veiksina, Santa ^a   Kopanchuk, Sergei ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

Binding model; Budded baculoviruses; Fluorescence anisotropy; G protein coupled receptors; Melanocortin 4 receptor; Residence time

Indexed keywords

FLUORESCENT DYE; G PROTEIN COUPLED RECEPTOR; IODINE NDP I 125; IODINE THIQ I 125; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; LIGAND; PROTEIN BINDING;

ANISOTROPY; BACULOVIRIDAE; BINDING AFFINITY; BINDING COMPETITION; BINDING KINETICS; DRUG BINDING SITE; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; FLUORESCENCE; FLUORESCENCE ANALYSIS; FLUORESCENCE ANGIOGRAPHY; FLUORESCENCE CORRELATION SPECTROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HORMONAL REGULATION; IC50; INHIBITION CONSTANT; LIGAND BINDING; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING ASSAY; RESIDENCE TIME; REVIEW; VIRUS PARTICLE; VIRUS RELEASE; BINDING SITE; DRUG DEVELOPMENT; HUMAN; KINETICS; METABOLISM; PHYSIOLOGY; PROCEDURES;

BINDING SITES; DRUG DISCOVERY; HUMANS; KINETICS; LIGANDS; MELANOCORTINS; PROTEIN BINDING; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84997417707     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.05.030     Document Type: Review

References (47)

1. [1] Rask-Andersen, M., Masuram, S., Schiöth, H.B., The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54 (2014), 9–26.
2. [2] Copeland, R.A., Pompliano, D.L., Meek, T.D., Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5 (2006), 730–739.
3. [3] Paton, W.D., Rang, H.P., The uptake of atropine and related drugs by intestinal smooth muscle of the guinea-pig in relation to acetylcholine receptors. Proc. R. Soc. Lond. [Biol.] 163 (1965), 1–44.
4. [4] Guo, D., Hillger, J.M., Ijzerman, A.P., Heitman, L.H., Drug-target residence time – a case for G protein-coupled receptors. Med. Res. Rev. 34 (2014), 856–892.
5. [5] Udenfriend, S., Gerber, L., Nelson, N., Scintillation proximity assay: a sensitive and continuous isotopic method for monitoring ligand/receptor and antigen/antibody interactions. Anal. Biochem. 161 (1987), 494–500.
6. 1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery. Br. J. Pharmacol. 171 (2014), 5816–5828.
7. [7] Glickman, J.F., Schmid, A., Ferrand, S., Scintillation proximity assays in high-throughput screening. Assay Drug Devel. Technol. 6 (2008), 433–455.
8. 1 receptor. Purinergic Signal. 12 (2016), 115–126.
9. [9] Heise, C.E., Sullivan, S.K., Crowe, P.D., Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor. J. Biomol. Screen. 12 (2007), 235–239.
10. [10] Melamed, E., Lahav, M., Atlas, D., Direct localisation of beta-adrenoceptor sites in rat cerebellum by a new fluorescent analogue of propranolol. Nature 261 (1976), 420–422.
11. [11] Sridharan, R., Zuber, J., Connelly, S.M., Mathew, E., Dumont, M.E., Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors. Biochim. Biophys. Acta (BBA) Biomembr. 1838 (2014), 15–33.
12. [12] Chen, L., Jin, L., Zhou, N., An update of novel screening methods for GPCR in drug discovery. Exp. Opin. Drug Discov. 7 (2012), 791–806.
13. [13] Lohse, M.J., Nuber, S., Hoffmann, C., Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling. Pharmacol. Rev. 64 (2012), 299–336.
14. [14] Hoffmann, C., Gaietta, G., Bunemann, M., Adams, S.R., Oberdorff-Maass, S., Behr, B., Vilardaga, J.P., Tsien, R.Y., Ellisman, M.H., Lohse, M.J., A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat. Meth. 2 (2005), 171–176.
15. [15] Tõntson, L., Kopanchuk, S., Rinken, A., Biarsenical ligands bind to endogenous G-protein alpha-subunits and enable allosteric sensing of nucleotide binding. BMC Biochem., 14, 2013, 37.
16. i-protein heterotrimer. J. Biol. Chem. 281 (2006), 24506–24511.
17. [17] Mazina, O., Luik, T., Kopanchuk, S., Salumets, A., Rinken, A., Characterization of the biological activities of human luteinizing hormone and chorionic gonadotropin by a Förster resonance energy transfer-based biosensor assay. Anal. Lett. 48 (2015), 2799–2809.
18. 1 receptor activation. J. Biomol. Screen. 17 (2012), 1096–1101.
19. [19] Briddon, S.J., Hill, S.J., Pharmacology under the microscope: the use of fluorescence correlation spectroscopy to determine the properties of ligand-receptor complexes. Trends Pharmacol. Sci. 28 (2007), 637–645.
20. [20] Corriden, R., Kilpatrick, L.E., Kellam, B., Briddon, S.J., Hill, S.J., Kinetic analysis of antagonist-occupied adenosine-A3 receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism. FASEB J. 28 (2014), 4211–4222.
21. [21] Rose, R.H., Briddon, S.J., Hill, S.J., A novel fluorescent histamine H(1) receptor antagonist demonstrates the advantage of using fluorescence correlation spectroscopy to study the binding of lipophilic ligands. Br. J. Pharmacol. 165 (2012), 1789–1800.
22. [22] Herrick-Davis, K., Grinde, E., Cowan, A., Mazurkiewicz, J.E., Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: the oligomer number puzzle. Mol. Pharmacol. 84 (2013), 630–642.
23. [23] Jones, J.W., Greene, T.A., Grygon, C.A., Doranz, B.J., Brown, M.P., Cell-free assay of G-protein-coupled receptors using fluorescence polarization. J. Biomol. Screen. 13 (2008), 424–429.
24. [24] Veiksina, S., Kopanchuk, S., Rinken, A., Fluorescence anisotropy assay for pharmacological characterization of ligand binding dynamics to melanocortin 4 receptors. Anal. Biochem. 402 (2010), 32–39.
25. [25] Huwiler, K.G., De Rosier, T., Hanson, B., Vogel, K.W., A fluorescence anisotropy assay for the muscarinic M1 G-protein-coupled receptor. Assay Drug Dev. Technol. 8 (2010), 356–366.
26. 1A receptors and their complexes with G-proteins in budded baculovirus particles using fluorescence anisotropy of Bodipy-FL-NAN-190. Neurochem. Int. 67 (2014), 32–38.
27. i-proteins by Bodipy-FL-GTPγS fluorescence anisotropy. Arch. Biochem. Biophys. 524 (2012), 93–98.
28. [28] Nosjean, O., Souchaud, S., Deniau, C., Geneste, O., Cauquil, N., Boutin, J.A., A simple theoretical model for fluorescence polarization binding assay development. J. Biomol. Screen. 11 (2006), 949–958.
29. 4 receptors. Methods Mol. Biol. 1272 (2015), 37–50.
30. [30] Tummino, P.J., Copeland, R.A., Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47 (2008), 5481–5492.
31. [31] Dahl, G., Akerud, T., Pharmacokinetics and the drug-target residence time concept. Drug Discov. Today 18 (2013), 697–707.
32. [32] Hoffmann, C., Castro, M., Rinken, A., Leurs, R., Hill, S.J., Vischer, H.F., Ligand residence time at G-protein-coupled receptors – why we should take our time to study it. Mol. Pharmacol. 88 (2015), 552–560.
33. [33] Wikberg, J.E.S., Mutulis, F., Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nat. Rev. Drug Discov. 7 (2008), 307–323.
34. [34] Gantz, I., Miwa, H., Konda, Y., Shimoto, Y., Tashiro, T., Watson, S.J., Delvalle, J., Yamada, T., Molecular cloning expression, and gene localization of a fourth melanocortin receptor. J. Biol. Chem. 268 (1993), 15174–15179.
35. [35] Schiöth, H.B., Muceniece, R., Wikberg, J.E.S., Characterisation of the melanocortin 4 receptor by radioligand binding. Pharmacol. Toxicol. 79 (1996), 161–165.
36. [36] Mutulis, F., Yahorava, S., Mutule, I., Yahorau, A., Kopanchuk, S., Veiksina, S., Rinken, A., Wikberg, J.E.S., A non-peptide radioiodinated high affinity melanocortin-4 receptor ligand. J. Label. Compd. Radiopharm. 46 (2003), 1007–1017.
37. [37] Mutulis, F., Yahorava, S., Mutule, I., Liepnish, E., Kopanchuk, S., Veiksina, S., Tars, K., Belyakov, S., Mishnev, A., Rinken, A., Wikberg, J.E.S., New substituted piperazines as ligands for melanocortin receptors. Correlation on the X-ray structure of THIQ. J. Med. Chem. 47 (2004), 4613–4626.
38. [38] Kopanchuk, S., Veiksina, S., Petrovska, R., Mutule, I., Szardenings, M., Rinken, A., Wikberg, J.E.S., Co-operative regulation of ligand binding to melanocortin receptor subtypes: evidence for interacting binding sites. Eur. J. Pharmacol. 512 (2005), 85–95.
39. [39] Kopanchuk, S., Veiksina, S., Mutulis, F., Mutule, I., Yahorava, S., Mandrika, I., Petrovska, R., Rinken, A., Wikberg, J.E.S., Kinetic evidence for tandemly arranged ligand binding sites in melanocortin 4 receptor complexes. Neurochem. Int. 49 (2006), 533–542.
40. [40] Strickland, S., Palmer, G., Massey, V., Determination of dissociation constants and specific rate constants of enzyme-substrate (or protein-ligand) interactions from rapid reaction kinetic data. J. Biol. Chem. 250 (1975), 4048–4052.
41. [41] Lepiku, M., Rinken, A., Järv, J., Fuxe, K., Kinetic evidence for isomerization of the dopamine receptor-raclopride complex. Neurochem. Int. 28 (1996), 591–595.
42. 2A receptors. Life Sci. 76 (2005), 1513–1526.
43. [43] Motulsky, H.J., Mahan, L.C., The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 25 (1984), 1–9.
44. [44] Mazina, O., Tõntson, L., Kopanchuk, S., Rinken, A., Application of baculovirus technology for studies of G protein-coupled receptor signaling. Fesenko, O., Yatsenko, L., Brodin, M., (eds.) Nanomaterials Imaging Techniques, Surface Studies and Applications, 2013, Springer, 339–348.
45. [45] Veiksina, S., Kopanchuk, S., Rinken, A., Budded baculoviruses as a tool for a homogeneous fluorescence anisotropy-based assay of ligand binding to G protein-coupled receptors: the case of melanocortin 4 receptors. Biochim. Biophys. Acta 1838 (2014), 372–381.
46. [46] Bailey, K., Bally, M., Leifert, W., Voros, J., McMurchie, T., G-protein coupled receptor array technologies: site directed immobilisation of liposomes containing the H1-histamine or M2-muscarinic receptors. Proteomics 9 (2009), 2052–2063.
47. [47] Makela, A.R., Oker-Blom, C., The baculovirus display technology–an evolving instrument for molecular screening and drug delivery. Comb. Chem. High Throughput Screen. 11 (2008), 86–98.